|
WO2020251847A1
|
|
Mycoplasma media formulations
|
|
WO2020219524A1
|
|
A 7h-pyrrolo[2,3-d]pyrimidine jak-inhibitor
|
|
WO2020163284A1
|
|
A genetically modified lactobacillus and uses thereof
|
|
WO2021037387A1
|
|
Porcine reproductive and respiratory syndrome vaccine virus
|
|
CN111565736A
|
|
Porcine G-CSF variants and uses thereof
|
|
WO2018204178A1
|
|
Bovine respiratory disease vaccine
|
|
CN109689079A
|
|
Ketoacidosis in bovine fibroblasts growth factor-2 1 and milk animal
|
|
EA036509B1
|
|
Pegylated porcine interferon and methods of use thereof
|
|
TW201738374A
|
|
Porcine Reproductive and Respiratory Syndrome Vaccine Virus
|
|
TW201628611A
|
|
Antiviral effects of narasin in swine feed
|
|
CA2996879A1
|
|
Methods and formulations for reducing ammonia emissions from bovines
|
|
EP3013977A2
|
|
Markers to predict macrocyclic lactone drug resistance in dirofilaria immitis, the causative agent of heartworm disease
|
|
US2015366983A1
|
|
Method of treating obesity in a companion animal comprising administering a modified canine leptin polypeptide
|
|
AU2013224751A1
|
|
Ectoparasiticidal methods and formulations
|
|
AU2005202712A1
|
|
Synergistic formulations
|
|
AU2004210544A1
|
|
Dosage form, device and methods of treatment
|
|
BRPI0418764A
|
|
Use of espinosine, or a physiologically acceptable derivative or salt thereof, in preparing medicinal products to promote or accelerate injury healing
|
|
AU2002330060B2
|
|
Method for controlling beetles
|
|
AU2001239017B2
|
|
Synergistic formulations
|
